
Recovery that keeps up with you
GH does its repair work overnight. Support that nightly pulse so one hard session no longer costs you the whole week.
The slide is not just age. After 30, your body’s own growth hormone drops about 15% every decade, and the deep sleep that releases it goes with it. Sermorelin, the GHRH peptide more men are turning to, signals your own pituitary to release your own GH again, in its natural nightly rhythm, the way it did at 25. Not synthetic hormone. Your hormone, switched back on.
Start your online visit →*First-month price on the 12-month plan; standard pricing applies thereafter. Subject to provider approval.
Here is what almost no one tells you. This is not a dozen separate problems. It is one. The deep slow-wave sleep that triggers your nightly growth hormone pulse fades as you age, and your GH output fades with it. Less GH means slower recovery, softer body composition, less drive, more fat that will not move. One signal weakening upstream, showing up as everything downstream. That upstream signal is a peptide called GHRH, and sermorelin is how you prompt it again. Fix the signal, and the rest has a real chance to follow.
Older men, mean age 68, brought back to the 24-hour growth hormone and IGF-1 levels of young men, mean age 26.
In a 1992 NIH study in the Journal of Clinical Endocrinology & Metabolism, twice-daily GHRH-(1-29), the same peptide molecule as sermorelin, raised 24-hour growth hormone and IGF-1 in healthy older men to levels statistically indistinguishable from young men. Not a claim. A published, peer-reviewed result with a PubMed ID you can open right now.
Corpas et al., JCEM 1992; PMID 1379256 ↗Sermorelin is a peptide, a signal your body already speaks. Instead of flooding you with synthetic HGH, it tells your own pituitary to make more of its own GH.
Switches your own GH back on, instead of flooding you like synthetic HGH.
Dosed before bed to work with your natural overnight repair window.
You prompt your own production, so your body keeps its own brakes.
A licensed provider reviews your intake and prescribes only if it fits.
Sermorelin supports your body’s own growth hormone; it does not replace it. Compounded medications are not FDA-approved and are prescribed only after review by a licensed provider. Results vary.
Every plan includes the full Telos Rx care experience. Prices shown are your first-month price. A licensed provider reviews your intake first. If you are not approved or not a fit, you pay nothing.
A licensed provider reviews your intake before anything ships. If you are not approved, you pay nothing.

GH does its repair work overnight. Support that nightly pulse so one hard session no longer costs you the whole week.

Deep sleep and GH release are tightly linked (general GH-axis context). It is the foundation everything else is built on.

Lower GH tracks with more belly fat and less lean mass (general GH-axis context). Give your training and diet a fair fight again.

GH helps maintain muscle and lean mass (general GH-axis context). The upstream signal behind keeping what you build.

When sleep, recovery, and body composition line up, men put it simply: their edge is back.

Not anti-aging hype. A clinician-guided protocol for the systems that quietly slip after 30. Age like a man who is paying attention.
Five minutes online. A licensed provider reviews your intake. Approved, and your personalized protocol ships free in two days. Not approved or not a fit, you pay nothing. First month from $40 on the 12-month plan.
Start your online visit →Compounded medications are not FDA-approved. Sermorelin is available only by prescription and is subject to medical approval by a licensed provider based on your online intake. This is an asynchronous online telehealth service and is not a substitute for in-person emergency care. Sermorelin is not intended to diagnose, treat, cure, or prevent any disease. Individual results vary and are not guaranteed. Testimonials reflect one individual’s experience and are not typical or a guarantee of results. Figures cited on this page are drawn from published research: sermorelin-direct studies (Corpas et al., JCEM 1992; Walker, Clinical Interventions in Aging 2006) are distinct from GHRH-class research (Steiger 1992) and general growth-hormone-axis context (Van Cauter, JAMA 2000; Endocrine Society Endotext), which are not sermorelin-specific and should not be read as such. Cited studies describe published research findings and do not represent a promise of any specific outcome from this product.